AR078797A1 - Inhibidores de la caseina quinasa, composiciones farmaceuticas y sus usos para tratar trastornos del snc - Google Patents
Inhibidores de la caseina quinasa, composiciones farmaceuticas y sus usos para tratar trastornos del sncInfo
- Publication number
- AR078797A1 AR078797A1 ARP100103948A ARP100103948A AR078797A1 AR 078797 A1 AR078797 A1 AR 078797A1 AR P100103948 A ARP100103948 A AR P100103948A AR P100103948 A ARP100103948 A AR P100103948A AR 078797 A1 AR078797 A1 AR 078797A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- hydrogen
- pharmaceutical compositions
- caseina
- quinasa
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Se dan a conocer también las composiciones farmacéuticas, los procedimientos de tratamiento, los procedimientos de síntesis y los productos intermedios correspondiente Reivindicacion 1: Un compuesto de formula (1): o sus sales farmacéuticamente aceptables caracterizado porque: A es un heterocicloalquilo de 4 a 7 miembros que contiene nitrogeno o, alternativamente, A se puede condensar directamente con el anillo al cual está unido mediante R1; L es alquilo C1-3; R1 es hidrogeno, alquilo C1-3 o cicloalquilo C3-4; cada R2 es independientemente alquilo C1-3, fluor, hidroxilo, alcoxi C1-3 o ciano; R3 es hidrogeno, alquilo C1-3 o cicloalquilo C3-4; R4 es un heteroarilo de 5 a 10 miembros con de 1 a 3 heteroátomos, sustituido opcionalmente con de uno a tres sustituyentes R7; R5 es hidrogeno o -N(R8)2; R6 es hidrogeno, halogeno o alquilo C1-3; cada R7 es independientemente halogeno, (CH2)t-Fq, alquilo C1-3, -CF3, -(CH2)t-cicloalquilo C3-4, -(CH2)t-O-alquilo C1-3, -(CH2)t-ciano o -(CH2)t-hidroxi; Z es N o CR9; cada R8 es independientemente hidrogeno o alquilo C1-3; R9 es hidrogeno, alquilo C1-3 o halogeno; m es 0, 1 o 2; n es 0, 1 o 2; q es 1, 2 o 3; t es 0, 1 o 2.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25550609P | 2009-10-28 | 2009-10-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR078797A1 true AR078797A1 (es) | 2011-12-07 |
Family
ID=43301770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100103948A AR078797A1 (es) | 2009-10-28 | 2010-10-28 | Inhibidores de la caseina quinasa, composiciones farmaceuticas y sus usos para tratar trastornos del snc |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8518944B2 (es) |
| EP (1) | EP2493876B1 (es) |
| JP (1) | JP5784620B2 (es) |
| KR (1) | KR101421852B1 (es) |
| CN (1) | CN102686580B (es) |
| AR (1) | AR078797A1 (es) |
| AU (1) | AU2010311035B2 (es) |
| CA (1) | CA2777632C (es) |
| DK (1) | DK2493876T3 (es) |
| ES (1) | ES2460065T3 (es) |
| HK (1) | HK1171220A1 (es) |
| HR (1) | HRP20140252T1 (es) |
| IL (1) | IL219190A0 (es) |
| IN (1) | IN2012DN03182A (es) |
| MX (1) | MX2012004997A (es) |
| PL (1) | PL2493876T3 (es) |
| PT (1) | PT2493876E (es) |
| RS (1) | RS53246B (es) |
| SI (1) | SI2493876T1 (es) |
| TW (1) | TW201125864A (es) |
| UY (1) | UY32977A (es) |
| WO (1) | WO2011051858A1 (es) |
| ZA (1) | ZA201202776B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2669693C (en) | 2006-11-15 | 2018-06-12 | Massachusetts Eye & Ear Infirmary | Generation of inner ear cells |
| EP2654750B1 (en) * | 2010-12-20 | 2017-03-08 | Pfizer Inc | Novel fused pyridine compounds as casein kinase inhibitors |
| US9556179B2 (en) | 2012-12-21 | 2017-01-31 | Bristol-Myers Squibb Company | Substituted imidazoles as casein kinase 1 D/E inhibitors |
| US9732065B2 (en) | 2013-05-30 | 2017-08-15 | Sumitomo Dainippon Pharma Co., Ltd. | Cyclic aminomethyl pyrimidine derivative |
| EP3102207B1 (en) | 2014-02-07 | 2022-05-11 | Agency For Science, Technology And Research | 2,4,5-tri-substituted azole-based casein kinase 1 inhibitors as inducers for cardiomyogenesis |
| WO2016022776A2 (en) | 2014-08-06 | 2016-02-11 | Massachusetts Eye And Ear Infirmary | Increasing atoh1 life to drive sensorineural hair cell differentiantion |
| WO2016149756A1 (en) | 2015-03-23 | 2016-09-29 | The University Of Melbourne | Treatment of respiratory diseases |
| WO2017096233A1 (en) * | 2015-12-04 | 2017-06-08 | Massachusetts Eye And Ear Infirmary | Treatment of hearing loss by inhibition of casein kinase 1 |
| KR20180117628A (ko) | 2016-01-29 | 2018-10-29 | 매사추세츠 아이 앤드 이어 인퍼머리 | 내이 지지 세포의 확장 및 분화 및 그의 사용 방법 |
| CN110753688A (zh) * | 2017-05-03 | 2020-02-04 | 墨尔本大学 | 用于治疗呼吸系统疾病的化合物 |
| US10973820B2 (en) | 2017-12-13 | 2021-04-13 | Facio Intellectual Property B.V. | Compounds for treatment of diseases related to DUX4 expression |
| WO2020049190A1 (en) * | 2018-09-09 | 2020-03-12 | Qanatpharma Gmbh | Use of casein kinase 1 inhibitors for treating vascular diseases |
| EP3877383A4 (en) * | 2018-11-07 | 2022-09-21 | The University of Melbourne | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF RESPIRATORY DISEASES |
| TW202112368A (zh) | 2019-06-13 | 2021-04-01 | 荷蘭商法西歐知識產權股份有限公司 | 用於治療有關dux4表現之疾病的抑制劑組合 |
| WO2021190616A1 (en) * | 2020-03-27 | 2021-09-30 | Gritscience Biopharmaceuticals Co., Ltd. | Methods for inhibiting casein kinases |
| WO2021190615A1 (en) * | 2020-03-27 | 2021-09-30 | Gritscience Biopharmaceuticals Co., Ltd. | Compounds as casein kinase inhibitors |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992012154A1 (en) * | 1990-12-31 | 1992-07-23 | Fujisawa Pharmaceutical Co., Ltd. | Imidazotriazine derivatives |
| IL110296A (en) | 1993-07-16 | 1999-12-31 | Smithkline Beecham Corp | Imidazole compounds process for their preparation and pharmaceutical compositions containing them |
| EP0889888A4 (en) * | 1996-03-25 | 2003-01-08 | Smithkline Beecham Corp | NEW TREATMENT OF LESIONS IN THE CENTRAL NERVOUS SYSTEM |
| US6239279B1 (en) | 1998-12-16 | 2001-05-29 | Smithkline Beecham Corporation | Synthesis for 4-aryl-5-pyrimidine imidazole substituted derivatives |
| GB0108770D0 (en) * | 2001-04-06 | 2001-05-30 | Eisai London Res Lab Ltd | Inhibitors |
| AU2002316279B2 (en) * | 2001-06-18 | 2007-08-23 | The Rockefeller University | Regulation of neuronal function through metabotropic glutamate receptor signaling pathways |
| WO2005061498A1 (en) * | 2003-12-11 | 2005-07-07 | Aventis Pharmaceuticals Inc. | Substituted 1h-pyrrolo[3,2-b, 3,2-c, and 2,3-c]pyridine-2-carboxamides and related analogs as inhibitors of casein kinase i epsilon |
| JO2629B1 (en) * | 2004-08-19 | 2012-06-24 | افينتيس فارما سوتيكالز انك | Branched carboxylic acid amides containing thienobirol, carboxylic acid amides containing pyrolithiazole, and the like as kinase inhibitors casein epsilon |
| DK1791537T3 (da) * | 2004-08-19 | 2010-03-01 | Aventis Pharma Inc | 3-arylthioindol-2-carboxamidderivater og analoger deraf som inhibitorer af casein-kinase |
| US8372851B2 (en) * | 2005-10-21 | 2013-02-12 | Exelixis, Inc. | Pyrazolo pyrimidines as casein kinase II (CK2) modulators |
| EP2308866A1 (de) * | 2009-10-09 | 2011-04-13 | Bayer CropScience AG | Phenylpyri(mi)dinylpyrazole und ihre Verwendung als Fungizide |
| EP2654750B1 (en) * | 2010-12-20 | 2017-03-08 | Pfizer Inc | Novel fused pyridine compounds as casein kinase inhibitors |
-
2010
- 2010-10-20 ES ES10774282.7T patent/ES2460065T3/es active Active
- 2010-10-20 MX MX2012004997A patent/MX2012004997A/es active IP Right Grant
- 2010-10-20 CA CA2777632A patent/CA2777632C/en not_active Expired - Fee Related
- 2010-10-20 PT PT107742827T patent/PT2493876E/pt unknown
- 2010-10-20 AU AU2010311035A patent/AU2010311035B2/en not_active Ceased
- 2010-10-20 RS RS20140157A patent/RS53246B/en unknown
- 2010-10-20 JP JP2012535977A patent/JP5784620B2/ja active Active
- 2010-10-20 SI SI201030539T patent/SI2493876T1/sl unknown
- 2010-10-20 KR KR1020127013537A patent/KR101421852B1/ko not_active IP Right Cessation
- 2010-10-20 EP EP10774282.7A patent/EP2493876B1/en active Active
- 2010-10-20 DK DK10774282.7T patent/DK2493876T3/en active
- 2010-10-20 CN CN201080059759.7A patent/CN102686580B/zh not_active Expired - Fee Related
- 2010-10-20 WO PCT/IB2010/054749 patent/WO2011051858A1/en active Application Filing
- 2010-10-20 IN IN3182DEN2012 patent/IN2012DN03182A/en unknown
- 2010-10-20 PL PL10774282T patent/PL2493876T3/pl unknown
- 2010-10-25 US US12/911,030 patent/US8518944B2/en active Active
- 2010-10-25 TW TW099136328A patent/TW201125864A/zh unknown
- 2010-10-27 UY UY0001032977A patent/UY32977A/es not_active Application Discontinuation
- 2010-10-28 AR ARP100103948A patent/AR078797A1/es not_active Application Discontinuation
-
2012
- 2012-04-15 IL IL219190A patent/IL219190A0/en unknown
- 2012-04-16 ZA ZA2012/02776A patent/ZA201202776B/en unknown
- 2012-11-21 HK HK12111895.9A patent/HK1171220A1/xx not_active IP Right Cessation
-
2014
- 2014-03-18 HR HRP20140252AT patent/HRP20140252T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2777632C (en) | 2014-02-25 |
| SI2493876T1 (sl) | 2014-04-30 |
| WO2011051858A1 (en) | 2011-05-05 |
| JP5784620B2 (ja) | 2015-09-24 |
| ZA201202776B (en) | 2013-06-26 |
| KR20120088759A (ko) | 2012-08-08 |
| TW201125864A (en) | 2011-08-01 |
| US20110098272A1 (en) | 2011-04-28 |
| AU2010311035A1 (en) | 2012-05-03 |
| US8518944B2 (en) | 2013-08-27 |
| IN2012DN03182A (es) | 2015-09-25 |
| DK2493876T3 (en) | 2014-03-10 |
| CN102686580B (zh) | 2014-09-10 |
| UY32977A (es) | 2011-05-31 |
| PT2493876E (pt) | 2014-03-20 |
| HK1171220A1 (en) | 2013-03-22 |
| CA2777632A1 (en) | 2011-05-05 |
| HRP20140252T1 (hr) | 2014-04-25 |
| JP2013509392A (ja) | 2013-03-14 |
| AU2010311035B2 (en) | 2013-05-16 |
| PL2493876T3 (pl) | 2014-06-30 |
| RS53246B (en) | 2014-08-29 |
| EP2493876B1 (en) | 2014-02-12 |
| MX2012004997A (es) | 2012-06-12 |
| EP2493876A1 (en) | 2012-09-05 |
| CN102686580A (zh) | 2012-09-19 |
| ES2460065T3 (es) | 2014-05-13 |
| IL219190A0 (en) | 2012-06-28 |
| KR101421852B1 (ko) | 2014-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR078797A1 (es) | Inhibidores de la caseina quinasa, composiciones farmaceuticas y sus usos para tratar trastornos del snc | |
| AR079260A1 (es) | Inhibidores de bencimidazol de la produccion de leucotrienos, un procedimiento para su preparacion, composiciones farmaceuticas que los comprenden y su empleo como medicamentos en el tratamiento de trastornos mediados por leucotrienos | |
| AR105845A1 (es) | Compuestos de heteroarilo bicíclicos fusionados como moduladores de la función irak4 | |
| AR086983A1 (es) | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak | |
| AR069796A1 (es) | Derivados de bencimidazol, sustituido por carboxilo o por hidroxilo, proceso para prepararlos y composiciones farmaceuticas que los contienen | |
| AR065322A1 (es) | 2-aminooxazolinas comoligandos de taar1 | |
| ES2655391T3 (es) | Inhibidores isoindolinona de fosfatidilinositol 3-quinasa | |
| PE20151781A1 (es) | Piridonamidas como moduladores de canales de sodio | |
| AR086538A1 (es) | COMPUESTOS PARA REDUCIR LA PRODUCCION DE b-AMILOIDE | |
| AR067646A1 (es) | Ariloxazoles sustituidos y su uso | |
| AR065015A1 (es) | Derivados de antranilamida, composiciones farmaceuticas que los contienen, y usos para el tratamiento del cancer | |
| AR053652A1 (es) | Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas | |
| PE20091734A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
| AR076435A1 (es) | Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| AR082111A1 (es) | Furopiridinas o tienopiridinas condensadas, composiciones farmaceuticas que las contienen utiles para tratar trastornos psicoticos y del sistema nervioso central, y metodo de preparacion de las mismas | |
| AR067444A1 (es) | Derivados de pirazinona, procesos de obtencion y composiciones farmaceuticas | |
| AR075510A1 (es) | Inhibidores del virus de la hepatitis c | |
| AR073136A1 (es) | Compuestos de pirrol | |
| AR079636A1 (es) | Antagonistas del receptor ccr2 y usos de los mismos | |
| AR066669A1 (es) | Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas. | |
| AR063601A1 (es) | Arilamidas sustituidas por tiazol u oxazol | |
| AR082889A1 (es) | Compuestos y composiciones para la inhibicion de nampt | |
| CO6140030A2 (es) | Derivados de 4-bencilftalazinona 2-sustituidos como antagonistas de histamina h1 y h3 | |
| CL2020002253A1 (es) | Derivados de 2,4 - diaminoquinazolina y usos médicos de los mismos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |